Literature DB >> 11444585

Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.

J D Hoehns1, R H Stanford, D R Geraets, K S Skelly, H C Lee, B L Gaul.   

Abstract

PURPOSE: To present a case of chlorpromazine-associated torsades de pointes, review established cases of ventricular arrhythmias associated with chlorpromazine, and describe the proarrhythmic characteristics of this drug. DATA SOURCES: Articles identified through a search of MEDLINE and IDIS from January 1966-November 2000 and thorough review of the article bibliographies. Patient cases also were identified from a search of the Food and Drug Administration's Adverse Event Reporting System database (November 1997-March 2001). Cases involving intentional overdoses of chlorpromazine were excluded.
RESULTS: In addition to the case reported herein, 12 cases of documented, chlorpromazine-associated ventricular arrhythmias were identified; five had characteristic features of torsades de pointes. Chlorpromazine delayed repolarization and produced electrocardiographic abnormalities; although, whether chlorpromazine induced torsades de pointes through a mechanism of early afterdepolarizations is unclear. Similar to other instances of drug-induced torsades de pointes, concurrent factors such as electrolyte deficiencies may place the patient at increased risk for arrhythmia.
CONCLUSIONS: Chlorpromazine can delay repolarization and produce electrocardiographic abnormalities. These can result infrequently in ventricular arrhythmias and torsades de pointes, particularly in patients with confounding factors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444585     DOI: 10.1592/phco.21.9.871.34565

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  10 in total

Review 1.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

Review 2.  QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.

Authors:  Katharina Wenzel-Seifert; Markus Wittmann; Ekkehard Haen
Journal:  Dtsch Arztebl Int       Date:  2011-10-14       Impact factor: 5.594

Review 3.  Antipsychotic drugs and QT interval prolongation.

Authors:  Wojciech Zareba; David A Lin
Journal:  Psychiatr Q       Date:  2003

4.  The antipsychotic drug chlorpromazine inhibits HERG potassium channels.

Authors:  Dierk Thomas; Kezhong Wu; Sven Kathöfer; Hugo A Katus; Wolfgang Schoels; Johann Kiehn; Christoph A Karle
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

Review 5.  Ether-a-go-go-related gene potassium channels: what's all the buzz about?

Authors:  Paul D Shepard; Carmen C Canavier; Edwin S Levitan
Journal:  Schizophr Bull       Date:  2007-09-28       Impact factor: 9.306

6.  QTc Prolongation and the Use of Antipsychotics: A Case Discussion.

Authors:  Jeff C. Huffman; Theodore A. Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-12

Review 7.  Ventricular repolarization measures for arrhythmic risk stratification.

Authors:  Francesco Monitillo; Marta Leone; Caterina Rizzo; Andrea Passantino; Massimo Iacoviello
Journal:  World J Cardiol       Date:  2016-01-26

8.  Detachment of surface membrane invagination systems by cationic amphiphilic drugs.

Authors:  Sangar Osman; Kirk A Taylor; Natalie Allcock; Richard D Rainbow; Martyn P Mahaut-Smith
Journal:  Sci Rep       Date:  2016-01-04       Impact factor: 4.379

9.  Acepromazine inhibits hERG potassium ion channels expressed in human embryonic kidney 293 cells.

Authors:  Young Shin Joo; Hong Joon Lee; Jin-Sung Choi; Ki-Wug Sung
Journal:  Korean J Physiol Pharmacol       Date:  2016-12-21       Impact factor: 2.016

10.  Issues in the management of acute agitation: how much current guidelines consider safety?

Authors:  Bruno Pacciardi; Mauro Mauri; Claudio Cargioli; Simone Belli; Biagio Cotugno; Luca Di Paolo; Stefano Pini
Journal:  Front Psychiatry       Date:  2013-05-07       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.